Today, it is increasingly recognized that more and more unmet medical needs may be met by tackling the undruggable targets in the realm of drug discovery. Along with other novel approaches, allostery has shown its potential to open another window for drug developers to broaden and diversify the drug space. Allostery is an inherent property of biomacromolecules in which topographically distinct binding sites within a protein are functionally coupled. Allosteric modulation of proteins enables exquisite control over a number of biological processes, presenting itself as a unique solution for drug developers to aim at undruggable targets. Furthermore, recent allosteric drugs, both approved and those still in clinical development stages, have simply demonstrated allostery as a proven drug discovery approach. NUTSEHLL is a suite of AI-based tools built upon a deep understanding of allosteric mechanism since 2013, when the enriched allosteric database was established around 2009. Currently, this well-established technology platform, in particular, the work flow know-how（SMA，PMA and PPA）enable to implement a complete compound discovery process from identification of the potential allosteric site, and all the way through to hit and lead molecule discovery, in conjunction with a strong medicinal chemistry capability. Thus far, NUTSHELL has been generating its own pipeline as well as enabling other academic and industry collaborators to develop allosteric drug. With our NUTSHELL proprietary platform and its early stage yet fast evolving allosteric based pipelines, NUTSHELL biotech is now becoming an oncology focused and novel target centered company and pioneering in allosteric drug discovery.
Dr. Yu was a former Associate Director of Drug Design at Novartis China, with over 25 years of global pharmaceutical experience in computer-aided drug discovery, cheminformatics and computational biology. Dr.Yu was the co-inventor of identification of novel inhibitors in both well-known targets and the novel target in the clinical phases. Dr. Yu currently serves as an Adjoint Advisor at Shanghai Technical University. Prior to Novartis, Dr. Yu worked at Abbvie and the Dow Chemical Company in the United States, and obtained his Ph.D. in physical chemistry at University of Massachusetts and a M.S. in computational chemistry, at University of Minnesota.
Dr. Zhuo has over 20 years of pharmaceutical and biotech experience in drug discovery with a track record of bringing more than 10 small molecules into clinical trials for multi-diseases including targeted therapy and immunotherapy approaches. Dr. Zhuo was the lead inventor of two Incyte approved drugs: (1) FGFRs’inhibitor Pemazyre (Pemigatinib, INCB54828) approved by FDA, as first target treatment for patients with advanced Cholangicarcinomaon, on Apr.2020, and (2) C-Met inhibitor TabrectaTM (Capmatinib, INC280) granted by FDA, as a first-line treatment for patients with MET-mutated advanced NSCLC on May,2020. Dr. Zhuo obtained his Ph.D.at NanKai University.
Mr.Yao has over 25-year hands-on and managerial experiences in drug discovery and development at both CRO and pharmaceutical company. Over 18-year career with Merck & Co. Inc. Mr.Yao was a key scientist in DMPK, pharmacology, safety assessment, comparative medicine, cardio-metabolic disorder areas and made significant contributions to a number of drugs launched in market such as Januvia® (sitagliptin), Janumet®, Zetia® (ezetimibe) and Vytorin®. Mr.Yao has also had broad experience in physiology and discovery biology. Mr.Yao graduated from JiaoTong University Medical School, Shanghai and received his M.S. of Molecular Biology from Montclair State University, New Jersey.
We believe that our people and culture are our greatest assets.
Innovation: We strive to be curious, inspired and think out of the box.
Teamwork: We hail from diverse backgrounds, different expertise, and deliver our promise to putting the team above self.
Humility: We aim to be open-minded and to learn from others.